Table 1.

Laboratory findings of cholesterol levels

	LDL-cholesterol (mg/dl)	HDL-cholesterol (mg/dl)
Before treatment	202	76
+ rosuvastatin	90	74
+ ezetimibe	66	76
+ evolocumab	11	64

LDL Low-density lipoprotein; HDL High-density lipoprotein

Legend: Low-density lipoprotein cholesterol level decreased from 202 mg/dl at baseline to 66 mg/dl after administration of rosuvastatin and ezetimibe. The intensive lipid lowering therapy with evolocumab, proprotein convertase subtilicin-kexin type 9 inhibitor, decreased further to 11 mg/dl